Side-by-side · Research reference
KPVvsThymalin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft13/39 cited
BHuman-MechanisticDraft12/40 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
Thymalin
Immune restorer · Russian peptide bioregulator
IM · Daily for 5–10 days · 1-2×/year
01Mechanism of Action
Parameter
KPV
Thymalin
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
T-cell precursors + thymus-axis maturation pathwayKhavinson 2002
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002
Feedback intact?
No melanocortin receptor binding
—
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Polypeptide fraction isolated from calf thymus extractKhavinson 2002
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
Thymalin
Frequency
Daily or 2–3× per week
Once daily during cycle
Lower / starter dose
100 mcg / day
2.5 mg / day
Evidence basis
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Russian clinical + in vitroKhavinson 2002
Duration
4–8 weeks per cycle
5–10 day cycles, 1–2× per year
Reconstitution
Bacteriostatic water (SQ form)
Saline or bacteriostatic water
Timing
No specific time; often taken with / before meals (oral)
Morning preferred
Half-life
Hours (estimated; rapid tissue uptake)
Hours (estimated)
04Side Effects & Safety
Parameter
KPV
Thymalin
Injection site reaction
Mild irritation
Mild erythema at IM site
GI symptoms
Rare nausea (oral form)
—
Long-term safety
Limited human data
Limited Western data
Pregnancy / OB
Avoid — insufficient data
Avoid
Allergic reaction
—
Rare hypersensitivity to bovine-derived polypeptide
Autoimmune flare
—
Theoretical risk in active autoimmune disease
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
Thymalin
- ·Pregnancy / breastfeeding
- ·Bovine protein hypersensitivity
Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
Thymalin
- ·Active autoimmune disease
- ·Concurrent immunosuppressant therapy
05Administration Protocol
Parameter
KPV
Thymalin
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
Add 1–2 mL saline or bacteriostatic water per 10 mg vial.
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
Intramuscular — deltoid or gluteal. Rotate sites.
3. Timing
Morning preferred; oral form taken with / before meals.
Morning preferred during cycle.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.
5. Needle
29–31G insulin syringe (SQ form).
23–25G, 25–38 mm IM needle.
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
Thymalin
+ Thymosin α-1
ModerateThymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.
- Thymalin
- 5–10 mg IM · daily × 7 days
- Thymosin α-1
- 1.6 mg SQ · 2× weekly during the cycle
- Primary benefit
- Broad thymic restoration + targeted immune activation